Company Filing History:
Years Active: 2015-2017
Title: **Innovative Cancer Detection Techniques by Terumasa Yamada**
Introduction
Terumasa Yamada, based in Osaka, Japan, stands out as a gifted inventor with a strong focus on advancing medical technology. With a total of two patents, his work primarily centers around the detection of cancer, aiming to improve diagnostic procedures and patient outcomes.
Latest Patents
Yamada's latest patents include groundbreaking methods for detecting cancer using the ICG fluorescence method. This innovative approach involves an administration step where indocyanine green is introduced into a living body. Following this, a target organ suspected of having cancer undergoes surgical exposure and is irradiated with excitation light of indocyanine green. An imaging step captures a near-infrared fluorescence intensity distribution image from the excited indocyanine green within the target organ. The process culminates in an identification step where areas showcasing near-infrared fluorescence in the intensity distribution image—excluding regions identified during preoperative examinations or intraoperative observations—are recognized as accessory cancer lesions.
Career Highlights
Terumasa Yamada has contributed significantly to the field of medical technology through his association with reputable organizations. Notably, he has worked with the Osaka Prefectural Hospital Organization and Hamamatsu Photonics K.K., where he has utilized his expertise to enhance cancer detection methods.
Collaborations
In his endeavors, Yamada has partnered with notable colleagues, including Osamu Ishikawa and Kunihito Gotoh. Their collaboration has played a vital role in the development and refinement of Yamada’s innovative techniques.
Conclusion
As an inventor, Terumasa Yamada continues to push the boundaries of cancer detection technology through his patented methods. His commitment to improving diagnostic capabilities highlights the essential role that innovation plays in the medical field, promising better health outcomes for patients in the future.